BioMarin Pharmaceutical Inc. (BM8.DE)
EUR 61.96
(-1.71%)
EUR 61.96
(-1.71%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 593.09 Million USD | -45.24% |
| 2022 | 1.08 Billion USD | 0.37% |
| 2021 | 1.07 Billion USD | 0.37% |
| 2020 | 1.07 Billion USD | 121.11% |
| 2019 | 486.23 Million USD | -41.45% |
| 2018 | 830.41 Million USD | 2.08% |
| 2017 | 813.52 Million USD | 23.12% |
| 2016 | 660.76 Million USD | -0.23% |
| 2015 | 662.28 Million USD | 0.66% |
| 2014 | 657.97 Million USD | 0.37% |
| 2013 | 655.56 Million USD | 101.8% |
| 2012 | 324.85 Million USD | -6.74% |
| 2011 | 348.32 Million USD | -7.73% |
| 2010 | 377.52 Million USD | -24.05% |
| 2009 | 497.08 Million USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 497.37 Million USD | 122.1% |
| 2006 | 223.94 Million USD | 5.17% |
| 2005 | 212.92 Million USD | -6.63% |
| 2004 | 228.03 Million USD | 82.43% |
| 2003 | 125 Million USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 3.96 Million USD | 6973.21% |
| 2000 | 56 Thousand USD | -34.12% |
| 1999 | 85 Thousand USD | -15.0% |
| 1998 | 100 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 593.6 Million USD | 0.09% |
| 2023 Q3 | 592.58 Million USD | -45.38% |
| 2023 Q2 | 1.08 Billion USD | 0.09% |
| 2023 Q4 | 593.09 Million USD | 0.09% |
| 2023 FY | 593.09 Million USD | -45.24% |
| 2023 Q1 | 1.08 Billion USD | 0.09% |
| 2022 Q4 | 1.08 Billion USD | 0.09% |
| 2022 FY | 1.08 Billion USD | 0.37% |
| 2022 Q1 | 1.08 Billion USD | 0.09% |
| 2022 Q2 | 1.08 Billion USD | 0.09% |
| 2022 Q3 | 1.08 Billion USD | 0.09% |
| 2021 Q2 | 1.07 Billion USD | 0.09% |
| 2021 FY | 1.07 Billion USD | 0.37% |
| 2021 Q3 | 1.07 Billion USD | 0.09% |
| 2021 Q4 | 1.07 Billion USD | 0.09% |
| 2021 Q1 | 1.07 Billion USD | 0.09% |
| 2020 Q1 | 486.71 Million USD | 0.1% |
| 2020 Q3 | 1.07 Billion USD | 0.09% |
| 2020 Q4 | 1.07 Billion USD | 0.09% |
| 2020 FY | 1.07 Billion USD | 121.11% |
| 2020 Q2 | 1.07 Billion USD | 120.5% |
| 2019 Q2 | 839.16 Million USD | 0.53% |
| 2019 Q3 | 843.61 Million USD | 0.53% |
| 2019 Q4 | 486.23 Million USD | -42.36% |
| 2019 FY | 486.23 Million USD | -41.45% |
| 2019 Q1 | 834.76 Million USD | 0.52% |
| 2018 Q4 | 830.41 Million USD | 0.52% |
| 2018 FY | 830.41 Million USD | 2.08% |
| 2018 Q1 | 817.67 Million USD | 0.51% |
| 2018 Q2 | 821.87 Million USD | 0.51% |
| 2018 Q3 | 826.11 Million USD | 0.52% |
| 2017 Q3 | 1.16 Billion USD | 72.44% |
| 2017 Q4 | 813.52 Million USD | -30.23% |
| 2017 Q2 | 676.2 Million USD | 1.16% |
| 2017 Q1 | 668.43 Million USD | 1.16% |
| 2017 FY | 813.52 Million USD | 23.12% |
| 2016 FY | 660.76 Million USD | -0.23% |
| 2016 Q2 | 645.68 Million USD | -3.34% |
| 2016 Q1 | 668 Million USD | 0.86% |
| 2016 Q3 | 653.17 Million USD | 1.16% |
| 2016 Q4 | 660.76 Million USD | 1.16% |
| 2015 Q1 | 655.49 Million USD | -0.38% |
| 2015 Q3 | 667.79 Million USD | 0.95% |
| 2015 Q4 | 662.28 Million USD | -0.82% |
| 2015 FY | 662.28 Million USD | 0.66% |
| 2015 Q2 | 661.49 Million USD | 0.92% |
| 2014 Q4 | 657.97 Million USD | 0.17% |
| 2014 Q2 | 650.87 Million USD | -1.59% |
| 2014 Q3 | 656.88 Million USD | 0.92% |
| 2014 Q1 | 661.41 Million USD | 0.89% |
| 2014 FY | 657.97 Million USD | 0.37% |
| 2013 Q4 | 655.56 Million USD | 737.14% |
| 2013 FY | 655.56 Million USD | 101.8% |
| 2013 Q2 | 109.82 Million USD | -0.02% |
| 2013 Q3 | 78.31 Million USD | -28.69% |
| 2013 Q1 | 109.84 Million USD | -66.19% |
| 2012 Q1 | 324.87 Million USD | -6.73% |
| 2012 Q4 | 324.85 Million USD | -0.0% |
| 2012 FY | 324.85 Million USD | -6.74% |
| 2012 Q3 | 324.86 Million USD | -0.0% |
| 2012 Q2 | 324.86 Million USD | -0.0% |
| 2011 Q1 | 377.52 Million USD | 0.0% |
| 2011 Q3 | 348.33 Million USD | -7.73% |
| 2011 Q4 | 348.32 Million USD | -0.0% |
| 2011 Q2 | 377.52 Million USD | -0.0% |
| 2011 FY | 348.32 Million USD | -7.73% |
| 2010 Q1 | 497.08 Million USD | 0.0% |
| 2010 FY | 377.52 Million USD | -24.05% |
| 2010 Q4 | 377.52 Million USD | -24.05% |
| 2010 Q3 | 497.08 Million USD | 0.0% |
| 2010 Q2 | 497.08 Million USD | 0.0% |
| 2009 Q2 | 497.08 Million USD | 0.0% |
| 2009 Q3 | 497.08 Million USD | 0.0% |
| 2009 Q4 | 497.08 Million USD | 0.0% |
| 2009 FY | 497.08 Million USD | 0.0% |
| 2009 Q1 | 497.08 Million USD | 0.0% |
| 2008 Q3 | 497.24 Million USD | -0.0% |
| 2008 Q1 | 497.3 Million USD | -0.02% |
| 2008 FY | - USD | -100.0% |
| 2008 Q2 | 497.24 Million USD | -0.01% |
| 2008 Q4 | 497.08 Million USD | -0.03% |
| 2007 Q4 | 497.37 Million USD | -11.86% |
| 2007 Q2 | 564.7 Million USD | 134.86% |
| 2007 FY | 497.37 Million USD | 122.1% |
| 2007 Q1 | 240.44 Million USD | 7.37% |
| 2007 Q3 | 564.32 Million USD | -0.07% |
| 2006 Q2 | 367.31 Million USD | -0.14% |
| 2006 FY | 223.94 Million USD | 5.17% |
| 2006 Q4 | 223.94 Million USD | -23.59% |
| 2006 Q3 | 293.08 Million USD | -20.21% |
| 2006 Q1 | 367.83 Million USD | 72.76% |
| 2005 Q2 | 215.96 Million USD | 49.35% |
| 2005 Q1 | 144.6 Million USD | -36.59% |
| 2005 FY | 212.92 Million USD | -6.63% |
| 2005 Q4 | 212.92 Million USD | -0.71% |
| 2005 Q3 | 214.44 Million USD | -0.7% |
| 2004 Q3 | 222.06 Million USD | 72.44% |
| 2004 Q2 | 128.77 Million USD | 3.02% |
| 2004 Q1 | 125 Million USD | 0.0% |
| 2004 FY | 228.03 Million USD | 82.43% |
| 2004 Q4 | 228.03 Million USD | 2.69% |
| 2003 Q3 | 125 Million USD | 0.0% |
| 2003 Q4 | 125 Million USD | 0.0% |
| 2003 Q2 | 125 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 125 Million USD | 0.0% |
| 2002 Q4 | - USD | -100.0% |
| 2002 Q3 | 2.91 Million USD | 0.0% |
| 2002 Q2 | - USD | -100.0% |
| 2002 Q1 | 3.5 Million USD | -11.56% |
| 2002 FY | - USD | -100.0% |
| 2001 Q4 | 3.96 Million USD | 2613.01% |
| 2001 Q2 | 198 Thousand USD | 321.28% |
| 2001 FY | 3.96 Million USD | 6973.21% |
| 2001 Q1 | 47 Thousand USD | -16.07% |
| 2001 Q3 | 146 Thousand USD | -26.26% |
| 2000 FY | 56 Thousand USD | -34.12% |
| 2000 Q4 | 56 Thousand USD | -11.11% |
| 2000 Q3 | 63 Thousand USD | -7.35% |
| 2000 Q2 | 68 Thousand USD | -11.69% |
| 2000 Q1 | 77 Thousand USD | -9.41% |
| 1999 Q4 | 85 Thousand USD | -15.0% |
| 1999 FY | 85 Thousand USD | -15.0% |
| 1999 Q2 | 26.1 Million USD | 26000.0% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 Q3 | 100 Thousand USD | -99.62% |
| 1998 FY | 100 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | -210.521% |
| CureVac N.V. | 36.81 Million EUR | -1510.84% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | -57.195% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | -57.195% |
| BRAIN Biotech AG | 25.19 Million EUR | -2254.206% |
| Formycon AG | 7.81 Million EUR | -7489.187% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -842280.729% |
| Medigene AG | 2.03 Million EUR | -29030.403% |